Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Pharmacokinetics and Pharmacodynamics of Peginterferon Beta-1a in Patients with Relapsing-Remitting Multiple Sclerosis: Data from the Pivotal Phase 3 ADVANCE Study
Multiple Sclerosis
(-)
194
Authors/Disclosures
Xiao Hu, PhD (Biogen Idec)
PRESENTER 		No disclosure on file
Joao O. Siffert, MD No disclosure on file
No disclosure on file
No disclosure on file
Ying Zhu No disclosure on file
Aaron Deykin, MD (Biogen Idec) No disclosure on file
No disclosure on file
Serena W. Hung, MD Dr. Hung has received personal compensation for serving as an employee of Atalanta Therapeutics. Dr. Hung has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for LoQus23 . Dr. Hung has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AS2 Bio. Dr. Hung has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for National Ataxia Foundation. Dr. Hung has or had stock in Atalanta Therapeutics.